Total Assets$XTALPI(02228.HK)AACR2026 disclosure: 1. AI+ Organoid Platform (Signet collaboration)
Technology iteration: Second-generation organoid throughput increased 10x, cycle shortened by 50%, cost reduced by 70%; added immune microenvironment co-culture, enabling precise prediction of immunotherapy response.
2. Pipeline matrix: Besides SIGX1094R (Claudin18.2, Phase I) and SIGX2649 (TEAD, Q2 IND), the third FIC pipeline (unnamed) has entered the PCC stage, targeting G protein-coupled receptor (GPCR) for pancreatic cancer, with data disclosure expected by the end of 2026.
3. Commercial rights: Agreement with Signet stipulates that Jingtai will receive up to 10% royalty after SIGX2649 commercialization; platform technology licensed to 3 pharmaceutical companies, with upfront payment + milestones totaling over USD 100 million.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
